Form UPLOAD - SEC-generated letter:
SEC Accession No. 0000000000-21-012325
Filing Date
2021-10-12
Accepted
2021-10-12 10:30:04
Documents
2

Document Format Files

Seq Description Document Type Size
1 filename1.pdf LETTER 27652
2 filename2.txt TEXT-EXTRACT 1496
  Complete submission text file 0000000000-21-012325.txt   40224
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filed for) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: UPLOAD
SIC: 2836 Biological Products, (No Diagnostic Substances)